Article

Allergan receives OK to market new formulation to lower IOP

The FDA has granted approval to Allergan to market its brimonidine tartrate ophthalmic solution 0.1% (Alphagan P), indicated to lower IOP in patients with primary open-angle glaucoma (POAG) or ocular hypertension.

The FDA has granted approval to Allergan to market its brimonidine tartrate ophthalmic solution 0.1% (Alphagan P), indicated to lower IOP in patients with primary open-angle glaucoma (POAG) or ocular hypertension.

The new solution is an optimized formulation of brimonidine tartrate ophthalmic solution 0.2% (Alphagan) to minimize drug exposure further while maintaining the drug’s favorable efficacy profile, the company said. The product is the latest advance in the company’s glaucoma franchise, which also includes brimonidine tartrate ophthalmic solution 0.15% (Alphagan P), according to Allergan.

According to clinical trial results, the 0.1% ophthalmic solution was proven to have IOP-lowering efficacy equivalent to the 0.2% ophthalmic solution, effectively lowering IOP in patients with POAG or ocular hypertension by about 2 to 6 mm Hg.

The new approved solution is contraindicated in patients receiving monoamine oxidase inhibitor therapy, according to Allergan.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) From MIGS to gene therapy: Inder Paul Singh, MD, celebrates the past and future of glaucoma care
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
© 2025 MJH Life Sciences

All rights reserved.